GOLPH3 SENSITIZES THE TUMOR SUPPRESSION EFFECT OF GEFITINIB ON GLIOMAS

Xu Wang,Zhaohao Wang,Yan Wang,Hao Zhang,Shao Xie,Peng Xie,Rutong Yu,Xiuping Zhou

DOI: https://doi.org/10.1093/neuonc/noy148.365

2018-01-01

Neuro-Oncology

Abstract:Golgi phosphoprotein 3 (GOLPH3) is associated with worse prognosis of gliomas, but its role and mechanism in glioma progression remain largely unknown. We previously reported that GOLPH3 promotes glioma progression by inhibiting EGFR endocytosis and degradation, leading to EGFR accumulation and PI3K-AKT pathway over-activation. In the current study, we examine whether GOLPH3 affects the response of glioma cells to gefitinib, an EGFR selective inhibitor. We found that both the immortalized and primary glioma cells with GOLPH3 over-expression hold higher EGFR protein levels on the cell membrane and exhibited higher sensitivity to gefitinib. In addition, primary glioma cells with higher GOLPH3 level exhibited stronger proliferation behavior. Importantly, GOLPH3 enhanced the anti-tumor effect of gefitinib in vivo. Consistently, after gefitinib treatment, tumors derived from GOLPH3 over-expression cells exhibited lower Ki67 positive and higher cleaved caspase-3 positive cells than control tumors. Taken together, our results demonstrate that GOLPH3 increases the sensitivity of glioma cells to gefitinib. Our study provides foundation for further exploring whether GOLPH3 high gliomas will more sensitive to gefitinib treatment in clinic and give ideas for developing new possible treatments for gliomas.